Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

A systematic review of atypical antipsychotic drugs in schizophrenia.

Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, Davies L, Torgerson D, Kleijnen J.

Health Technol Assess. 2003;7(13):1-193. Review. No abstract available.

2.
3.

Which atypical antipsychotic.

Thomas CS, Lewis S.

Br J Psychiatry. 1998 Feb;172:106-9. No abstract available.

PMID:
9519061
4.

Cost-effectiveness of atypical antipsychotic medications versus conventional medication.

Hanrahan P, Luchins DJ, Fabian R, Tolley G.

Expert Opin Pharmacother. 2006 Sep;7(13):1749-58. Review.

PMID:
16925502
6.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

7.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
8.

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW.

Arch Gen Psychiatry. 2006 Oct;63(10):1079-87.

PMID:
17015810
9.

[Priority for atypical antipsychotic drugs? Current studies clarify the issues].

Dose M.

Psychiatr Prax. 2007 Jan;34(1):46-9. German. No abstract available.

PMID:
17265252
11.

Developing a policy for second-generation antipsychotic drugs.

Rosenheck RA, Sernyak MJ.

Health Aff (Millwood). 2009 Sep-Oct;28(5):w782-93. doi: 10.1377/hlthaff.28.5.w782. Epub 2009 Jul 21.

12.

Practical applications of recent antipsychotic effectiveness data.

[No authors listed]

J Clin Psychiatry. 2007 Jan;68(1):151-62. No abstract available.

PMID:
17284143
13.

[Expensive but nevertheless cost effect? Pharmacoeconomics of atypical neuroleptics].

Laux G, Günther W.

Pharm Unserer Zeit. 2002;31(6):572-6. Review. German. No abstract available.

PMID:
12481515
14.

[Pharmaco-economic aspects of antidepressants and antipsychotic drugs].

Laux G.

Psychiatr Prax. 2003 May;30 Suppl 2:S90-3. Review. German.

PMID:
14509049
15.

[Treatment of schizophrenia with "atypical antipsychotic drugs". Quality of life as a measure of treatment success].

[No authors listed]

Krankenpfl J. 2002;40(7-9):230-1. German. No abstract available.

PMID:
12514869
16.

Antipsychotic safety and efficacy concerns.

Meyer JM.

J Clin Psychiatry. 2007;68 Suppl 14:20-6. Review.

17.
18.

Atypical antipsychotic drugs.

Mackin P, Thomas SH.

BMJ. 2011 Mar 4;342:d1126. doi: 10.1136/bmj.d1126. No abstract available.

PMID:
21378070
19.

[Consumption and cost of antipsychotic drugs].

Pérez J, Marín N, Vallano A, Castells X, Capellà D.

Actas Esp Psiquiatr. 2005 Mar-Apr;33(2):110-6. Spanish.

PMID:
15768318
20.

Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.

Keith S.

Expert Rev Neurother. 2009 Jan;9(1):9-31. doi: 10.1586/14737175.9.1.9. Review.

PMID:
19102665

Supplemental Content

Support Center